Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle, Mitesh J Borad, Nilofer S Azad, Razelle Kurzrock, Ghassan K Abou-Alfa, Ben George, John Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christopher J Sweeney, Claire F Friedman, Ron Bose, David R Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard Burris

Open source

DOI: 10.1016/s1470-2045(21)00336-3
Published: 2021-09
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-21-00336-3,
  title = {Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study},
  author = {Milind Javle and Mitesh J Borad and Nilofer S Azad and Razelle Kurzrock and Ghassan K Abou-Alfa and Ben George and John Hainsworth and Funda Meric-Bernstam and Charles Swanton and Christopher J Sweeney and Claire F Friedman and Ron Bose and David R Spigel and Yong Wang and Jonathan Levy and Katja Schulze and Vaikunth Cuchelkar and Arisha Patel and Howard Burris},
  year = {2021},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(21)00336-3},
  url = {https://doi.org/10.1016/s1470-2045(21)00336-3}
}

RIS

TY  - JOUR
TI  - Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
AU  - Milind Javle
AU  - Mitesh J Borad
AU  - Nilofer S Azad
AU  - Razelle Kurzrock
AU  - Ghassan K Abou-Alfa
AU  - Ben George
AU  - John Hainsworth
AU  - Funda Meric-Bernstam
AU  - Charles Swanton
AU  - Christopher J Sweeney
AU  - Claire F Friedman
AU  - Ron Bose
AU  - David R Spigel
AU  - Yong Wang
AU  - Jonathan Levy
AU  - Katja Schulze
AU  - Vaikunth Cuchelkar
AU  - Arisha Patel
AU  - Howard Burris
PY  - 2021
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(21)00336-3
UR  - https://doi.org/10.1016/s1470-2045(21)00336-3
ER  -

APA

Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., Friedman, C. F., Bose, R., Spigel, D. R., Wang, Y., Levy, J., Schulze, K., Cuchelkar, V., Patel, A., & Burris, H. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00336-3

Source records

crossref · retrieved 2026-09-26T15:21:38.447Z